



Pacific Center for
Emerging Infectious Diseases
Research



UNIVERSITY
of HAWAII
MĀNOA

Department of Tropical Medicine, Medical Microbiology & Pharmacology

JOHN A BURNS SCHOOL OF MEDICINE, UNIVERSITY OF HAWAII AT MANOA

Hendra Virus and Nipah Virus Therapy and Vaccine

Hendra virus (HeV) and Nipah virus (NiV) are highly pathogenic bat-borne paramyxoviruses, which emerged in the 1990s causing disease outbreaks in livestock and people, are important trans-boundary biological threats. HeV appeared in Australia and since 1994 there have been 59 spillover events and more than 100 horse deaths, and 4 of 7 human case fatalities. NiV first appeared in Malaysia and subsequent outbreaks have occurred in Bangladesh and India, totaling >600 human cases with fatality rates from 40–100%. A human monoclonal antibody targeting the viral G glycoprotein has been shown to be an effective post-exposure treatment against HeV and NiV in animals and has been used in 15 individuals by emergency protocol. A subunit vaccine based on the HeV G glycoprotein can provide complete protection against HeV or NiV infection in several animal models, and a vaccine (Equivac® HeV) is now available in Australia to protect horses from HeV infection.

Christopher C. Broder, Ph.D.

*Professor and Graduate Program Director
Department of Microbiology and Immunology
Uniformed Services University of the Health Sciences
Bethesda, Maryland*

Tuesday, October 10, 2017 at 10:15 a.m.
John A. Burns School of Medicine, Kaka'ako Campus
Medical Education Building Auditorium (Room 315)
For further information, contact (808) 692-1654

This seminar is supported by grant P30GM114737 (COBRE) from the National Institutes of Health.



Papaya



Kalamansi



Annona



Litchi